[Special Stock] SillaJen Surges 18% on IND Approval for Solid Tumor Treatment Phase 1 in Korea
Shinilajen surged more than 18% after receiving approval from the Ministry of Food and Drug Safety for its domestic Phase 1 clinical trial plan (IND) related to solid cancer treatment.
As of 9:57 AM on the 14th, Shinilajen was trading at 6,980 KRW, up 18.51% from the previous day.
Hot Picks Today
!["Stock Set to Double: This Company Smiles Every Time a Data Center Is Built [Click e-Stock]"](https://cwcontent.asiae.co.kr/asiaresize/93/2026050416112750184_1777878687.jpg)
"Stock Set to Double: This Company Smiles Every...
- "Continuous Groundwater Pumping Causes Mexico City to Sink 24cm Annually... 'Gia...
- “She Shouted, ‘The Rope Isn’t Tied!’... Chinese Woman Falls from 168m Cliff ...
- Samsung Electronics Officially Decides to Withdraw Some Home Appliance Businesse...
- "Prime Minister in Underwear?"... Italy's Meloni Posts Herself to Warn of Deepfa...
The day before, Shinilajen announced that the Ministry of Food and Drug Safety had approved the Phase 1 clinical trial plan for BAL0891 as a monotherapy and in combination with chemotherapy for patients with advanced solid tumors.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
